ZA200608178B - Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins - Google Patents

Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Info

Publication number
ZA200608178B
ZA200608178B ZA200608178A ZA200608178A ZA200608178B ZA 200608178 B ZA200608178 B ZA 200608178B ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 A ZA200608178 A ZA 200608178A ZA 200608178 B ZA200608178 B ZA 200608178B
Authority
ZA
South Africa
Prior art keywords
modulation
polypeptide sequence
viral proteins
sequence involved
protein
Prior art date
Application number
ZA200608178A
Other languages
English (en)
Inventor
Renard Martial
Mangeney Marianne
Heidmann Thierry
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Sud Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Sud Xi filed Critical Roussy Inst Gustave
Publication of ZA200608178B publication Critical patent/ZA200608178B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200608178A 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins ZA200608178B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30

Publications (1)

Publication Number Publication Date
ZA200608178B true ZA200608178B (en) 2008-10-29

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608178A ZA200608178B (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Country Status (14)

Country Link
US (2) US8178657B2 (de)
EP (1) EP1732585B1 (de)
JP (1) JP5060284B2 (de)
CN (1) CN1961001B (de)
AT (1) ATE472334T1 (de)
AU (1) AU2005229411B2 (de)
BR (1) BRPI0509497B1 (de)
CA (1) CA2561376C (de)
DE (1) DE602005022056D1 (de)
ES (1) ES2347445T3 (de)
IL (1) IL178205A (de)
MX (1) MXPA06011272A (de)
WO (1) WO2005095442A1 (de)
ZA (1) ZA200608178B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP2402447A1 (de) 2005-03-30 2012-01-04 Viroxis Endogener Retrovirus und ENV-Gen codierte Proteine als Target zur Krebsbehandlung
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
CN102326079B (zh) 2009-01-09 2015-04-15 国家科研中心 新型受体结合配体及其在检测具有生物学益处的细胞中的用途
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
IN2014CN00547A (de) 2011-07-20 2015-04-03 Merial Ltd
KR102059918B1 (ko) * 2011-12-07 2020-02-11 비록시스 에스.아.에스. 돌연변이형 렌티바이러스 env 단백질 및 이의 약물로서의 용도
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US9974852B2 (en) 2013-06-07 2018-05-22 Viroxis Sas Mutated non-primate lentiviral Env proteins and their use as drugs
EP3309178A4 (de) * 2015-06-11 2019-05-08 Keio University Fusionsprotein oder konjugiertes protein, träger zur intrazellulären abgabe, teilpeptid, zellmembran-permeationsverstärker, dna und vektor
JP7037486B2 (ja) * 2015-10-01 2022-03-16 エイムヴィオン・アクティエセルスカブ 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
JP7277466B2 (ja) * 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および/または治療における使用のためのワクチン
KR20210070305A (ko) 2018-09-18 2021-06-14 브이엔브이 뉴코 인크. Arc 기반 캡시드 및 이의 용도
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
AU4616289A (en) * 1988-12-13 1990-06-21 Colorado State University Research Foundation Prototype felv isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
WO2002047720A2 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US8178657B2 (en) 2012-05-15
WO2005095442A1 (en) 2005-10-13
US20120189647A1 (en) 2012-07-26
ATE472334T1 (de) 2010-07-15
WO2005095442A8 (en) 2006-11-02
EP1732585A1 (de) 2006-12-20
CA2561376A1 (en) 2005-10-13
CN1961001B (zh) 2012-09-05
US8597657B2 (en) 2013-12-03
BRPI0509497B1 (pt) 2022-07-19
JP5060284B2 (ja) 2012-10-31
IL178205A0 (en) 2006-12-31
AU2005229411B2 (en) 2010-11-18
DE602005022056D1 (de) 2010-08-12
US20080008683A1 (en) 2008-01-10
JP2008506357A (ja) 2008-03-06
CA2561376C (en) 2016-06-21
EP1732585B1 (de) 2010-06-30
CN1961001A (zh) 2007-05-09
BRPI0509497A (pt) 2007-09-11
MXPA06011272A (es) 2007-04-17
IL178205A (en) 2015-05-31
ES2347445T3 (es) 2010-10-29
AU2005229411A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
ZA200608178B (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2007053188A3 (en) Production of multivalent virus like particles
PL1685243T3 (pl) Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
WO2006136084A8 (fr) Proteines de fusion de proteines structurales recombinantes du coronavirus sars, leur production et leurs utilisations
EP4234571A3 (de) Virale vektoren mit modifizierten transduktionsprofilen sowie verfahren zu ihrer herstellung und verwendung
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
IL187168A (en) Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
WO2010132092A3 (en) Cytidine deaminase fusions and related methods
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
EP2208796A3 (de) Polypeptide mit Nukleinsäurebindungsaktivität und Zusammensetzungen und Verfahren zur Nukleinsäurenamplifikation
DE60134786D1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
ATE478965T1 (de) Lentivirusvektoren und deren verwendung
MX2009006398A (es) Genotecas de proteinas de fusion de transferrina.
UA95446C2 (ru) Мутаци в генах oas1
MX2009012326A (es) Peptidos de señalizacion.
WO2004024750A3 (en) Cd44-binding ligands
WO2005003315A3 (en) Compositions and methods for peptide-assisted transfection
IN2012DN05145A (de)
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
DE60114018D1 (de) Von zellen präsentierte peptide
EP2395358A3 (de) Kovalentes Anbinden von Funktionsgruppen an Proteine und Substrate dafür
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same